Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) dropped 1.3% on Friday . The stock traded as low as $1.45 and last traded at $1.47. Approximately 129,515 shares traded hands during trading, a decline of 49% from the average daily volume of 253,318 shares. The stock had previously closed at $1.49.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lowered their price objective on Repare Therapeutics from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Friday, March 7th.
View Our Latest Stock Report on RPTX
Repare Therapeutics Stock Performance
The company's 50-day moving average price is $1.27 and its 200-day moving average price is $1.44. The firm has a market capitalization of $63.48 million, a PE ratio of -0.74 and a beta of 0.84.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in RPTX. Tower Research Capital LLC TRC lifted its stake in Repare Therapeutics by 204.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company's stock worth $45,000 after purchasing an additional 23,127 shares during the last quarter. Vontobel Holding Ltd. lifted its position in shares of Repare Therapeutics by 45.8% during the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company's stock worth $46,000 after buying an additional 11,000 shares during the last quarter. Lynx1 Capital Management LP acquired a new position in shares of Repare Therapeutics in the 4th quarter valued at $104,000. JPMorgan Chase & Co. boosted its holdings in shares of Repare Therapeutics by 2,144,950.0% in the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company's stock valued at $112,000 after buying an additional 85,798 shares in the last quarter. Finally, Stifel Financial Corp grew its position in shares of Repare Therapeutics by 73.1% in the 4th quarter. Stifel Financial Corp now owns 89,500 shares of the company's stock valued at $117,000 after buying an additional 37,800 shares during the last quarter. Hedge funds and other institutional investors own 85.09% of the company's stock.
About Repare Therapeutics
(
Get Free Report)
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
Featured Articles
Before you consider Repare Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repare Therapeutics wasn't on the list.
While Repare Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
